Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination
Background: Merkel cell carcinoma (MCC) is a rare but very aggressive skin tumor that develops after integration of a truncated form of the large T-antigen (truncLT) of the Merkel cell polyomavirus (MCV) into the host’s genome. Therapeutic vaccination with dendritic cells (DCs) loaded with tumor ant...
Main Authors: | Kerstin F. Gerer, Michael Erdmann, Sine R. Hadrup, Rikke Lyngaa, Lena-Marie Martin, Reinhard E. Voll, Beatrice Schuler-Thurner, Gerold Schuler, Niels Schaft, Stefanie Hoyer, Jan Dörrie |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2017-07-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758834017712630 |
Similar Items
-
BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy
by: Jan Dörrie, et al.
Published: (2018-01-01) -
Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update
by: Jan Dörrie, et al.
Published: (2020-01-01) -
CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia
by: Dennis C. Harrer, et al.
Published: (2019-06-01) -
RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma
by: Dennis C. Harrer, et al.
Published: (2017-08-01) -
Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance
by: Manuel Wiesinger, et al.
Published: (2019-08-01)